Previous Close | 0.0070 |
Open | 0.0065 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0065 - 0.0085 |
52 Week Range | 0.0065 - 0.2200 |
Volume | |
Avg. Volume | 360,272 |
Market Cap | 221,388 |
Beta (5Y Monthly) | 1.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business developments, financing and the 2024 annual meeting. ...
Establishes Strong Financial Base To Advance Development of Novel Cancer Immunotherapies CLEVELAND, OH / ACCESSWIRE / January 2, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, ...
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit.Event:December 7th Investor SummitPresentation: December 7th, 2023 @ 1:30 PM ETLocation:https://us06web.zoom.us/webinar/register/WN_ps0tLsybTUyu5q9_J_OXYA1x1s will be available for qualified investorsThe conference is completely complimentary to qualified investorsAbout NovAccess GlobalNovAccess Global is a preclinical,